Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab on Microglia in Relapsing MS
NCT04510220Phase 3Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ofatumumab in multiple sclerosis (MS), sponsored by Brigham and Women's Hospital. Started Sep 2020; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04510220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510220.